Pfizer, who once ruled the cardiac drug scene with Lipitor and Norvasc, is pulling out of heart medications to focus on more profitable areas like oncology and Alzheimer’s disease.
They got burned pretty badly with the HDL-raising drug torcetrapib, and their combo statin-hypertension medication Caduet is having anemic sales.
Profits obviously dictate where innovation should lie. The same thing happened to antibiotics where there hasn’t been a breakthrough drug in years.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Get free updates delivered free to your inbox.
Search thousands of physician, PA, NP, and CRNA jobs now.
Comments are moderated before they are published. Please read the comment policy.
